Johnson & Johnson has a consensus price target of $171.24, established from looking at the 95 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, Cantor Fitzgerald, and HSBC on May 16, 2024, May 6, 2024, and April 18, 2024. With an average price target of $186.67 between RBC Capital, Cantor Fitzgerald, and HSBC, there's an implied 23.57% upside for Johnson & Johnson from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/16/2024 | Buy Now | 15.85% | RBC Capital | Shagun Singh | → $175 | Reiterates | Outperform → Outperform | Get Alert |
05/06/2024 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
04/18/2024 | Buy Now | 12.54% | HSBC | Morten Herholdt | $169 → $170 | Upgrade | Hold → Buy | Get Alert |
04/17/2024 | Buy Now | 10.55% | Morgan Stanley | Terence Flynn | $168 → $167 | Maintains | Equal-Weight | Get Alert |
04/17/2024 | Buy Now | 15.85% | RBC Capital | Shagun Singh | $181 → $175 | Maintains | Outperform | Get Alert |
04/17/2024 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
04/17/2024 | Buy Now | 12.54% | B of A Securities | Geoff Meacham | $180 → $170 | Maintains | Neutral | Get Alert |
04/15/2024 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
03/13/2024 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
02/28/2024 | Buy Now | 19.82% | RBC Capital | Shagun Singh | → $181 | Reiterates | Outperform → Outperform | Get Alert |
02/20/2024 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
02/06/2024 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
01/24/2024 | Buy Now | 11.88% | Morgan Stanley | Terence Flynn | $170 → $169 | Maintains | Equal-Weight | Get Alert |
01/24/2024 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
01/24/2024 | Buy Now | 19.82% | RBC Capital | Shagun Singh | → $181 | Reiterates | Outperform → Outperform | Get Alert |
01/23/2024 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
01/09/2024 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
01/03/2024 | Buy Now | 15.85% | Raymond James | Jayson Bedford | $172 → $175 | Maintains | Outperform | Get Alert |
12/13/2023 | Buy Now | 7.9% | Wells Fargo | Larry Biegelsen | $170 → $163 | Downgrade | Overweight → Equal-Weight | Get Alert |
12/06/2023 | Buy Now | 19.82% | RBC Capital | Shagun Singh | $178 → $181 | Maintains | Outperform | Get Alert |
12/01/2023 | Buy Now | 17.83% | RBC Capital | Shagun Singh | → $178 | Reiterates | Outperform → Outperform | Get Alert |
12/01/2023 | Buy Now | 19.16% | UBS | Danielle Antalffy | → $180 | Upgrade | Neutral → Buy | Get Alert |
11/20/2023 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
11/17/2023 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
10/23/2023 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
10/18/2023 | Buy Now | 13.2% | Morgan Stanley | Terence Flynn | $174 → $171 | Maintains | Equal-Weight | Get Alert |
10/18/2023 | Buy Now | 13.86% | Raymond James | Jayson Bedford | $179 → $172 | Maintains | Outperform | Get Alert |
10/18/2023 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
10/12/2023 | Buy Now | 7.24% | Barclays | Matt Miksic | $158 → $162 | Maintains | Equal-Weight | Get Alert |
10/11/2023 | Buy Now | 42.33% | Cantor Fitzgerald | Louise Chen | → $215 | Reiterates | Overweight → Overweight | Get Alert |
The latest price target for Johnson & Johnson (NYSE: JNJ) was reported by RBC Capital on May 16, 2024. The analyst firm set a price target for $175.00 expecting JNJ to rise to within 12 months (a possible 15.85% upside). 55 analyst firms have reported ratings in the last year.
The latest analyst rating for Johnson & Johnson (NYSE: JNJ) was provided by RBC Capital, and Johnson & Johnson reiterated their outperform rating.
The last upgrade for Johnson & Johnson happened on April 18, 2024 when HSBC raised their price target to $170. HSBC previously had a hold for Johnson & Johnson.
The last downgrade for Johnson & Johnson happened on December 13, 2023 when Wells Fargo changed their price target from $170 to $163 for Johnson & Johnson.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Johnson & Johnson, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Johnson & Johnson was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
While ratings are subjective and will change, the latest Johnson & Johnson (JNJ) rating was a reiterated with a price target of $0.00 to $175.00. The current price Johnson & Johnson (JNJ) is trading at is $151.06, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.